Neurocrine Biosciences, Inc. (NBIX)
USD 109.68
(2.9%)
USD 109.68
(2.9%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.88 Billion USD | 26.76% |
| 2022 | 1.48 Billion USD | 31.34% |
| 2021 | 1.13 Billion USD | 8.38% |
| 2020 | 1.04 Billion USD | 32.71% |
| 2019 | 788.1 Million USD | 74.65% |
| 2018 | 451.24 Million USD | 179.19% |
| 2017 | 161.62 Million USD | 977.51% |
| 2016 | 15 Million USD | -24.12% |
| 2015 | 19.76 Million USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 2.91 Million USD | -94.51% |
| 2012 | 53.14 Million USD | -31.36% |
| 2011 | 77.41 Million USD | 131.08% |
| 2010 | 33.5 Million USD | 1034.47% |
| 2009 | 2.95 Million USD | -25.71% |
| 2008 | 3.97 Million USD | 224.75% |
| 2007 | 1.22 Million USD | -96.88% |
| 2006 | 39.23 Million USD | -68.33% |
| 2005 | 123.88 Million USD | 45.45% |
| 2004 | 85.17 Million USD | -38.76% |
| 2003 | 139.07 Million USD | 670.73% |
| 2002 | 18.04 Million USD | -56.25% |
| 2001 | 41.24 Million USD | 182.71% |
| 2000 | 14.58 Million USD | -13.17% |
| 1999 | 16.8 Million USD | 5.0% |
| 1998 | 16 Million USD | -38.7% |
| 1997 | 26.1 Million USD | 35.94% |
| 1996 | 19.2 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 515.29 Million USD | 0.02% |
| 2024 Q2 | 590.2 Million USD | 14.54% |
| 2024 Q3 | 622.1 Million USD | 5.4% |
| 2023 Q1 | 420.4 Million USD | 2.04% |
| 2023 Q4 | 515.2 Million USD | 3.29% |
| 2023 FY | 1.88 Billion USD | 26.76% |
| 2023 Q3 | 498.8 Million USD | 10.18% |
| 2023 Q2 | 452.7 Million USD | 7.68% |
| 2022 Q4 | 412 Million USD | 6.21% |
| 2022 FY | 1.48 Billion USD | 31.34% |
| 2022 Q2 | 378.2 Million USD | 21.76% |
| 2022 Q3 | 387.9 Million USD | 2.56% |
| 2022 Q1 | 310.6 Million USD | -0.45% |
| 2021 Q1 | 236.6 Million USD | -4.56% |
| 2021 Q4 | 312 Million USD | 5.41% |
| 2021 Q3 | 296 Million USD | 2.46% |
| 2021 Q2 | 288.9 Million USD | 22.1% |
| 2021 FY | 1.13 Billion USD | 8.38% |
| 2020 Q2 | 302.4 Million USD | 27.54% |
| 2020 Q4 | 247.9 Million USD | -4.1% |
| 2020 FY | 1.04 Billion USD | 32.71% |
| 2020 Q1 | 237.1 Million USD | -2.87% |
| 2020 Q3 | 258.5 Million USD | -14.52% |
| 2019 Q2 | 183.58 Million USD | 32.64% |
| 2019 FY | 788.1 Million USD | 74.65% |
| 2019 Q1 | 138.4 Million USD | 5.26% |
| 2019 Q3 | 222.09 Million USD | 20.98% |
| 2019 Q4 | 244.1 Million USD | 9.91% |
| 2018 FY | 451.24 Million USD | 179.19% |
| 2018 Q3 | 151.75 Million USD | 56.6% |
| 2018 Q4 | 131.49 Million USD | -13.35% |
| 2018 Q1 | 71.08 Million USD | -24.79% |
| 2018 Q2 | 96.9 Million USD | 36.32% |
| 2017 Q2 | 6.33 Million USD | 0.0% |
| 2017 Q4 | 94.51 Million USD | 55.52% |
| 2017 FY | 161.62 Million USD | 977.51% |
| 2017 Q3 | 60.77 Million USD | 859.34% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | 15 Million USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2016 FY | 15 Million USD | -24.12% |
| 2016 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | 19.76 Million USD | 0.0% |
| 2015 FY | 19.76 Million USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2013 FY | 2.91 Million USD | -94.51% |
| 2013 Q4 | 730 Thousand USD | 0.14% |
| 2013 Q3 | 729 Thousand USD | -0.14% |
| 2013 Q2 | 730 Thousand USD | 0.0% |
| 2013 Q1 | 730 Thousand USD | -96.67% |
| 2012 Q3 | 9.35 Million USD | -11.47% |
| 2012 Q4 | 21.94 Million USD | 134.55% |
| 2012 FY | 53.14 Million USD | -31.36% |
| 2012 Q2 | 10.56 Million USD | -6.2% |
| 2012 Q1 | 11.26 Million USD | 1.41% |
| 2011 Q3 | 41.63 Million USD | 242.47% |
| 2011 Q4 | 11.11 Million USD | -73.32% |
| 2011 FY | 77.41 Million USD | 131.08% |
| 2011 Q1 | 12.51 Million USD | -8.38% |
| 2011 Q2 | 12.15 Million USD | -2.84% |
| 2010 Q4 | 13.65 Million USD | -5.47% |
| 2010 Q3 | 14.44 Million USD | 211.18% |
| 2010 FY | 33.5 Million USD | 1034.47% |
| 2010 Q2 | 4.64 Million USD | 516.6% |
| 2010 Q1 | 753 Thousand USD | 1.76% |
| 2009 Q1 | 747 Thousand USD | 2.47% |
| 2009 FY | 2.95 Million USD | -25.71% |
| 2009 Q3 | 733 Thousand USD | 0.0% |
| 2009 Q4 | 740 Thousand USD | 0.95% |
| 2009 Q2 | 733 Thousand USD | -1.87% |
| 2008 Q2 | 734 Thousand USD | -58.08% |
| 2008 Q4 | 729 Thousand USD | -4.2% |
| 2008 FY | 3.97 Million USD | 224.75% |
| 2008 Q1 | 1.75 Million USD | 229.14% |
| 2008 Q3 | 761 Thousand USD | 3.68% |
| 2007 FY | 1.22 Million USD | -96.88% |
| 2007 Q1 | 104 Thousand USD | -98.9% |
| 2007 Q4 | 532 Thousand USD | -1.48% |
| 2007 Q3 | 540 Thousand USD | 1025.0% |
| 2007 Q2 | 48 Thousand USD | -53.85% |
| 2006 Q2 | 9.24 Million USD | -52.54% |
| 2006 Q4 | 9.44 Million USD | 778.96% |
| 2006 FY | 39.23 Million USD | -68.33% |
| 2006 Q3 | 1.07 Million USD | -88.38% |
| 2006 Q1 | 19.47 Million USD | 38.02% |
| 2005 FY | 123.88 Million USD | 45.45% |
| 2005 Q3 | 64.74 Million USD | 95.2% |
| 2005 Q1 | 11.86 Million USD | -35.82% |
| 2005 Q2 | 33.16 Million USD | 179.58% |
| 2005 Q4 | 14.11 Million USD | -78.21% |
| 2004 FY | 85.17 Million USD | -38.76% |
| 2004 Q1 | 16.94 Million USD | -37.57% |
| 2004 Q2 | 15.04 Million USD | -11.17% |
| 2004 Q3 | 34.7 Million USD | 130.59% |
| 2004 Q4 | 18.48 Million USD | -46.73% |
| 2003 Q2 | 44.96 Million USD | 19.23% |
| 2003 FY | 139.07 Million USD | 670.73% |
| 2003 Q3 | 29.25 Million USD | -34.93% |
| 2003 Q4 | 27.13 Million USD | -7.26% |
| 2003 Q1 | 37.71 Million USD | 872.56% |
| 2002 Q3 | 4.98 Million USD | 17.89% |
| 2002 FY | 18.04 Million USD | -56.25% |
| 2002 Q4 | 3.87 Million USD | -22.18% |
| 2002 Q2 | 4.22 Million USD | -14.73% |
| 2002 Q1 | 4.95 Million USD | -61.37% |
| 2001 Q2 | 3.32 Million USD | -4.59% |
| 2001 Q3 | 21.59 Million USD | 548.83% |
| 2001 FY | 41.24 Million USD | 182.71% |
| 2001 Q1 | 3.48 Million USD | -1.61% |
| 2001 Q4 | 12.83 Million USD | -40.57% |
| 2000 FY | 14.58 Million USD | -13.17% |
| 2000 Q2 | 2.94 Million USD | 5.9% |
| 2000 Q4 | 3.54 Million USD | -33.4% |
| 2000 Q3 | 5.32 Million USD | 80.93% |
| 2000 Q1 | 2.77 Million USD | -33.86% |
| 1999 Q1 | 3.6 Million USD | -20.0% |
| 1999 Q2 | 3.8 Million USD | 5.56% |
| 1999 Q3 | 5.2 Million USD | 36.84% |
| 1999 FY | 16.8 Million USD | 5.0% |
| 1999 Q4 | 4.2 Million USD | -19.23% |
| 1998 Q2 | 2.3 Million USD | -43.9% |
| 1998 Q1 | 4.1 Million USD | -33.87% |
| 1998 FY | 16 Million USD | -38.7% |
| 1998 Q4 | 4.5 Million USD | -11.76% |
| 1998 Q3 | 5.1 Million USD | 121.74% |
| 1997 Q1 | 8.9 Million USD | -4.3% |
| 1997 Q3 | 6.2 Million USD | 29.17% |
| 1997 Q4 | 6.2 Million USD | 0.0% |
| 1997 FY | 26.1 Million USD | 35.94% |
| 1997 Q2 | 4.8 Million USD | -46.07% |
| 1996 Q1 | 2.2 Million USD | 0.0% |
| 1996 FY | 19.2 Million USD | 0.0% |
| 1996 Q2 | 5.5 Million USD | 150.0% |
| 1996 Q3 | 2.2 Million USD | -60.0% |
| 1996 Q4 | 9.3 Million USD | 322.73% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 116.33 Million USD | -1522.14% |
| Theratechnologies Inc. | 81.76 Million USD | -2207.984% |
| Safety Shot Inc | 202.67 Thousand USD | -931019.554% |
| Cosmos Health Inc. | 53.37 Million USD | -3435.426% |
| Cronos Group Inc. | 88.84 Million USD | -2024.134% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -326.237% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -335.679% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -5740.835% |
| ProPhase Labs, Inc. | 44.38 Million USD | -4151.757% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -14718.218% |
| Dynavax Technologies Corporation | 232.28 Million USD | -712.411% |
| Radius Health, Inc. | 2.88 Billion USD | 34.526% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -97753.406% |
| Alvotech | 91.43 Million USD | -1963.893% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -7732.635% |
| Alpha Teknova, Inc. | 36.68 Million USD | -5044.205% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -306.379% |
| SCYNEXIS, Inc. | 140.14 Million USD | -1246.572% |
| Harrow Health, Inc. | 130.19 Million USD | -1349.463% |
| Biofrontera Inc. | 34.07 Million USD | -5438.728% |
| DURECT Corporation | 8.54 Million USD | -21976.509% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -210.623% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -287.641% |
| OptiNose, Inc. | 70.98 Million USD | -2558.374% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -28873.589% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -3630.7% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -4671.126% |
| SIGA Technologies, Inc. | 139.91 Million USD | -1248.726% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -1371.297% |
| Shineco, Inc. | 9.8 Million USD | -19152.476% |
| Phibro Animal Health Corporation | 1.01 Billion USD | -85.432% |
| Procaps Group S.A. | 409.92 Million USD | -360.358% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -144838.556% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Viatris Inc. | 15.42 Billion USD | 87.767% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -7732.635% |
| Rockwell Medical, Inc. | 83.61 Million USD | -2156.973% |
| Incannex Healthcare Limited | 12 Thousand USD | -15725733.333% |
| Aytu BioPharma, Inc. | 81 Million USD | -2229.696% |
| Tilray Brands, Inc. | 788.94 Million USD | -139.194% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -232.959% |
| PetIQ, Inc. | 1.1 Billion USD | -71.249% |
| Silver Spike Investment Corp. | 11.72 Million USD | -15998.606% |
| Journey Medical Corporation | 79.18 Million USD | -2283.274% |
| Alimera Sciences, Inc. | 80.75 Million USD | -2236.85% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -32311.1% |
| Assertio Holdings, Inc. | 152.06 Million USD | -1140.95% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Embecta Corp. | 1.12 Billion USD | -68.371% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -175215.053% |
| Procaps Group, S.A. | 409.92 Million USD | -360.358% |
| PainReform Ltd. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -6648.561% |
| Hempacco Co., Inc. | 4.04 Million USD | -46545.312% |
| Talphera, Inc. | 651 Thousand USD | -289777.112% |
| Pacira BioSciences, Inc. | 674.97 Million USD | -179.579% |
| Alvotech | 91.43 Million USD | -1963.893% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | -45.561% |
| Kamada Ltd. | 144.75 Million USD | -1203.617% |
| Indivior PLC | 1.09 Billion USD | -72.653% |
| Currenc Group, Inc. | 53.25 Million USD | -3443.493% |
| Evoke Pharma, Inc. | 5.18 Million USD | -36326.072% |
| Flora Growth Corp. | 76.07 Million USD | -2380.709% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -175215.053% |
| Evolus, Inc. | 202.08 Million USD | -833.815% |
| HUTCHMED (China) Limited | 837.99 Million USD | -125.191% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | -192.848% |
| Akanda Corp. | 2.16 Million USD | -87263.638% |